Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects

As obesity evolves as a global pandemic, the use of drugs to treat it is booming. The latest among these are Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Along with their use, the incidence of adverse events has become more common. Although severe effects have been mentioned, details and a...

Повний опис

Бібліографічні деталі

Автори:	Pranjal Sharma, Venkata Buddhavarapu, Gagandeep Dhillon, Ram Kishun Verma, Ramprakash Devadoss, James Raynor, Ripudaman Munjal, Harpreet Grewal, Rahul Kashyap
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2024-08-01
Серія:	Endocrines
Предмети:	GLP-1 agonist glucagon-like peptide-1 receptor agonist semaglutide liraglutide dulaglutide side effects
Онлайн доступ:	https://www.mdpi.com/2673-396X/5/3/23
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!